FDA Accepts Supplement for Finasteride by Sun Pharma
The FDA has accepted a supplemental application for Finasteride (ANDA090508) submitted by Sun Pharma.
Published: August 1, 2026
Updated: August 1, 2026
Author: Humanexa Intelligence
Therapeutic area: Urology / 5-alpha reductase inhibitor
Company: Sun Pharma
Asset: Finasteride
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Sun Pharma
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of Sun Pharma's supplemental application for Finasteride is a significant regulatory milestone that could enhance their competitive positioning in the urology market. Portfolio teams should closely monitor the review timeline and potential market implications.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for FDA review and any subsequent approvals or market launches.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.